Trial Profile
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Rectal cancer
- Focus Therapeutic Use
- 29 May 2015 Primary endpoint was not met (Pathologic Complete Response Rate) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 May 2015 5-year clinical outcome results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 28 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.